
Thoughtfully Transforming Healthcare Delivery TM
- Our Clinical Pathways
- Solutions
- …
- Our Clinical Pathways
- Solutions
Thoughtfully Transforming Healthcare Delivery TM
- Our Clinical Pathways
- Solutions
- …
- Our Clinical Pathways
- Solutions
Traumatic Brain Injury (TBI) Clinical Pathway
Introducing the only proven objective clinical pathway for the diagnosis and management of traumatic brain injury
Neurotrauma Workup & Care Plan Management
The key to superior TBI care is an evidence-based pathway that delivers objective diagnosis and consistent care plan management
Neurotrauma Assessment Test (NAT™)
The Neurotrauma Assessment Test (NAT™), developed by Brazos Neuroscience and offered through the BioConnetiX TBI Diagnostic Pathway, is a mass spectrometry–based assay that provides definitive biochemical evidence of traumatic brain injury (TBI) at any stage, delivering mechanistically grounded insight into injury severity and the risk of long-term cognitive impairment. When performed within the BioConnetiX pathway, NAT™ becomes part of a coordinated diagnostic and care management framework – linking laboratory data with neurological assessment, care plan guidance, one-touch access to e-consults with specialists, longitudinal tracking, and outcome analytics. This integrated model transforms NAT™ from a standalone test into a powerful clinical decision-support tool that enables objective diagnosis, progression monitoring, and informed treatment planning.
BioConnetiX Closes the Gap Between Lab-Developed Tests and Patient Care - Transforming Top Science into Managed Care Pathways
We don’t simply provide access to a test – we build the system that makes it work. From provider training and neurologist coordination to embedded protocols, lab logistics, and longitudinal reporting, BioConnetiX manages every step. By integrating care delivery, data, and accountability, we turn advanced diagnostics like NTAT™ into measurable outcomes for patients, providers, and payers alike.
Integrated Intelligence – A digital clinical infrastructure for efficient, consistent, and connected care - ensuring your network operates from a single playbook.
Public Health Advantage – Population-level analytics inform AI/ML insights, risk modeling, and prevention strategies—improving outcomes and reducing costs.
The Science
NAT™ quantifies concentrations of four clinically validated neurotrauma-related proteins – Glial Fibrillary Acidic Protein (GFAP), Ubiquitin C-terminal Hydrolase L1 (UCH-L1), S100ß, and Neurofilament-Heavy Chain (NF-H) – alongside two functional genetic markers known to influence post-TBI outcomes: Apolipoprotein E (APOE) and Methylenetetrahydrofolate Reductase (MTHFR). This multiplexed approach captures complementary dimensions of traumatic brain injury, integrating biochemical evidence of acute and chronic neurotrauma with genetic predisposition data.
Clinical Leadership – A Multi-Disciplinary Approach
Kevin Rosenblatt, M.D., Ph.D., and Peter Bryant-Greenwood, M.D. – the developers of NAT™ – serve in dual roles that maintain both scientific rigor and clinical integration. As laboratory directors at Brazos Neuroscience, they oversee test development, validation, and quality control. As medical directors at BioConnetiX, they participate with other medical directors on multi-disciplinary pathway design and clinical decision-support protocols, ensuring the test’s application aligns with best practices in patient care.
BioConnetiX builds and manages the system that operationalizes these pathways, aggregating data into dynamic dashboards that enable longitudinal monitoring, advanced analytics, and AI-driven insights. To safeguard impartiality, medical directors and laboratory owners hold no ownership interest in BioConnetiX, and BioConnetiX maintains no financial stake in the testing laboratories. Independent subspecialist physicians – also with no ownership ties – conduct utilization review to ensure every test is applied appropriately, delivering precision, accountability, and value across the care continuum.
Limitations of Conventional TBI Diagnostics
The current standard of care for traumatic brain injury (TBI) diagnostics is centered almost exclusively on the acute post-injury period, typically within the first 24 to 72 hours. Conventional clinical tools – which include symptom inventories, neurocognitive screens (e.g., MACE, MoCA), and structural imaging (CT, MRI) – are designed to detect gross abnormalities, intracranial bleeding, or acute functional impairments. However, these tools exhibit low sensitivity for mild-to-moderate TBI (mmTBI), and their diagnostic utility rapidly diminishes beyond the acute phase. As a result, the vast majority of TBI cases – especially those without overt radiographic findings – go undetected or misclassified, resulting in avoidable and often long-term neurological compromise.
Moreover, once the immediate injury window has passed, no clinically validated method exists to definitively confirm prior TBI, assess cumulative exposure, or determine recovery status. This not only impairs timely intervention but also precludes effective longitudinal care, contributing to persistent post-concussive symptoms (PCS), cognitive and functional decline, and elevated long-term disability rates.
NAT™ closes this diagnostic blind spot. NAT™ provides objective confirmation across any phase of injury evolution and recovery: Acute (0–72 hours post-injury), Post-Acute (4 days to 6 weeks post-injury), and Chronic (6 weeks to more than 5 years post-injury), while our managed care framework ensures those results are translated into standardized, protocol-driven care that reduces cost variability and prevents patients from slipping through gaps in the system.
Differentiators – NAT™ vs. Conventional TBI Diagnostics
- Objective Diagnosis – Delivers diagnostic accuracy, replacing subjective inputs with objective biomarkers to enable confident, evidence-based decisions
- Risk Stratification – Generates risk score (low, medium, high) for prolonged cognitive impairment, supporting targeted interventions that optimize recovery outcomes
- Longitudinal Monitoring – Enables serial tracking of neurological status to confirm injury resolution, detect ongoing neurodegeneration, and assess cumulative exposure
Integrate advanced molecular diagnostics and evidence-based personalized medicine into your primary care network with confidence - and remote support any time you need it
BioConnetiX empowers any system to integrate advanced diagnostics and care plan management into everyday care.
Redefine What's Possible in TBI Care
Contact Us to Learn More About Integrating a TBI Pathway into Your Network
FAX: (469) 599-7188
© 2025 BioConnetiX